These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36358930)

  • 1. Tirzepatide-Friend or Foe in Diabetic Cancer Patients?
    Samuel SM; Varghese E; Kubatka P; Büsselberg D
    Biomolecules; 2022 Oct; 12(11):. PubMed ID: 36358930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide.
    Boye KS; Sapin H; Dong W; Williamson S; Lee CJ; Thieu VT
    Diabetes Ther; 2023 Nov; 14(11):1867-1887. PubMed ID: 37668888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.
    Boye KS; Thieu VT; Sapin H; Lee CJ; Landó LF; Brown K; Bray R; Wiese RJ; Patel H; Rodríguez Á; Yu M
    Diabetes Ther; 2023 Nov; 14(11):1833-1852. PubMed ID: 37526908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
    Frías JP
    Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond.
    Dutta P; Kumar Y; Babu AT; Giri Ravindran S; Salam A; Rai B; Baskar A; Dhawan A; Jomy M
    Cureus; 2023 May; 15(5):e38379. PubMed ID: 37265914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes.
    Nowak M; Nowak W; Grzeszczak W
    Endokrynol Pol; 2022; 73(4):745-755. PubMed ID: 35593668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program.
    le Roux CW; Zhang S; Aronne LJ; Kushner RF; Chao AM; Machineni S; Dunn J; Chigutsa FB; Ahmad NN; Bunck MC
    Obesity (Silver Spring); 2023 Jan; 31(1):96-110. PubMed ID: 36478180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis.
    Lisco G; De Tullio A; Disoteo O; De Geronimo V; Piazzolla G; De Pergola G; Giagulli VA; Jirillo E; Guastamacchia E; Sabbà C; Triggiani V
    Front Endocrinol (Lausanne); 2022; 13():920541. PubMed ID: 36157450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials.
    Min T; Bain SC
    Diabetes Ther; 2021 Jan; 12(1):143-157. PubMed ID: 33325008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
    Urva S; Coskun T; Loghin C; Cui X; Beebe E; O'Farrell L; Briere DA; Benson C; Nauck MA; Haupt A
    Diabetes Obes Metab; 2020 Oct; 22(10):1886-1891. PubMed ID: 32519795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
    De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
    Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity.
    Gallwitz B
    Front Endocrinol (Lausanne); 2022; 13():1004044. PubMed ID: 36313764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes.
    Matza LS; Stewart KD; Landó LF; Patel H; Boye KS
    Patient; 2022 May; 15(3):367-377. PubMed ID: 35513765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes.
    Kaneko S
    touchREV Endocrinol; 2022 Jun; 18(1):10-19. PubMed ID: 35949358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes].
    Scheen AJ; Radermecker RP; Paquot N
    Rev Med Suisse; 2022 Aug; 18(792):1539-1544. PubMed ID: 36004653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health.
    Bucheit J; Ayers J; Pamulapati L; Browning A; Sisson E
    J Cardiovasc Pharmacol; 2022 Aug; 80(2):171-179. PubMed ID: 35767712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.